Roche Breast Cancer Drug Appears to Greatly Extend Patients’ Lives

Perjeta, approved by the F.D.A. in 2012, prolonged median survival time about 16 months in a trial of 808 people with metastatic breast cancer.

via NYT > Health http://ift.tt/107IPRA

via All Health and Fitness http://ift.tt/1nqlW6F